Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
Labetalol hydrochloride is a combined alpha and beta-adrenergic blocking agent administered intravenously as a solution for acute hypertension management. It is used primarily in hospital settings for rapid blood pressure control in hypertensive emergencies and perioperative hypertension. The drug works by blocking both alpha-1 and beta-adrenergic receptors, providing dual vasodilation and heart rate reduction.
Product is in peak commercial phase with moderate competitive pressure (30), indicating stable revenue streams but requiring ongoing market defense strategies.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on labetalol at Hikma offers stable, hospital-focused commercial roles in a peak-lifecycle product with moderate competitive pressure. Career growth centers on hospital formulary strategy, managed care negotiations, and clinical adoption across critical care and perioperative settings rather than pipeline advancement.
Worked on LABETALOL HYDROCHLORIDE at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo